Advertisement
DALLAS, May 17, 2019 /PRNewswire-PRWeb/ -- Veran Medical continues its mission to help physicians diagnose and treat early stage lung cancer with the launch of two, new navigation software applications. These software applications are designed to help diagnose and guide treatment of small suspicious nodules likely to be early stage lung cancer. Veran is also debuting a new Always-On Tip Tracked® Triple Needle Brush. The new software and new tip tracked instrument will be debuted at the annual American Thoracic Society meeting in Dallas, TX.
Veran has innovated and improved its industry leading software, making it even simpler for physicians to use for both the SPiN Planning™ and SPiN Drive® software applications to assist in the early diagnosis and treatment of lung cancer. New capabilities have also been added for integration of Cone Beam CT, PET scans, and the ability to display blood vessels during both planning and navigation. In addition, Veran has made a great advancement on physician and hospital support with the enhancement of vSupport™ Connect, an on-demand secure screen sharing for live physician directed clinical support.
Veran Medical will also debut a new Always-On Tip Tracked® Triple Needle Brush. This electromagnetic tip tracked tool will help physicians take more samples to assist in the early diagnosis of lung cancer. Since this new instrument will be tip tracked, physicians will not need to use fluoroscopy during sampling.
"The expanding adoption of lung cancer screening has given us a real opportunity to catch cancer earlier and save lives, but only if we can help physicians reach the smallest nodules," said Veran Medical CEO Jason Pesterfield. "Our new software applications and Always-On Tip Tracked® Triple Needle Brush provide additional flexibility to help physicians reach and guide treatment for early stage cancer when patients have the best prognosis."
Veran's next generation SPiN Thoracic Navigation System™ offers an industry leading precision thoracic guidance platform that allows lung specialists to seamlessly transition between a navigated endobronchial approach and a navigated transthoracic approach utilizing SPiN Perc™, to help physicians diagnose lung cancer earlier. A published clinical study utilizing a multi-modality approach, including Veran's SPiN System™ and SPiN Perc™, have demonstrated a 92% diagnostic yield.
Lung Cancer remains the number one cancer killer worldwide. 94 million current or former smokers remain at elevated risk in the U.S. alone. More than 8 million people in the U.S. currently meet the criteria for lung cancer screening. When suspicious lesions are discovered, patients need answers. But mounting clinical data suggests that a large percentage of the hundreds of thousands of bronchoscopies performed every year on suspected lung cancer patients are non-diagnostic—delaying potential lifesaving therapy.
About Veran Medical Technologies
Veran is a privately held medical device company headquartered in St. Louis, MO. The company's mission is to empower physicians to diagnose cancer earlier and to enable precision therapy to save lives. In the United States, lung cancer kills more people each year than breast, prostate, pancreatic and colon cancers combined.
Veran has developed and commercialized an FDA cleared, next generation electromagnetic thoracic navigation platform called the SPiN Thoracic Navigation System™. Veran's breakthrough technology has been adopted by leading cancer centers throughout the United States. Veran provides physicians with a full line of bronchoscopic brushes, needles, forceps and steerable catheters with tiny electromagnetic sensors embedded in the tips for precise navigation. The combination of these proprietary Always-On Tip Tracked® instruments and Veran's exclusive patient respiratory gating technology enables physicians to accurately access lung nodules by accounting for nodule movement during patient breathing, a common challenge for lung specialists.
Another challenge lung specialists face is that approximately 40% of lung nodules lie outside of an airway, making them very difficult to reach endobronchially, and traditionally requiring an additional procedure. Veran's SPiN Thoracic Navigation System™ is the first and only FDA cleared technology that enables Pulmonologists or Thoracic Surgeons the ability to safely and accurately access lung nodules outside of an airway using SPiN Perc™, a navigated transthoracic needle. With SPiN Perc™, Veran combines endobronchial navigation with percutaneous navigation, allowing physicians to access all lung nodules in a single procedure, regardless of nodule size or location. This eliminates the cost and risk of unnecessary procedures and empowers physicians to provide a same day diagnosis for their patients. The early diagnosis and treatment of lung cancer has been proven to save lives.
SOURCE Veran Medical
Advertisement
Veran has innovated and improved its industry leading software, making it even simpler for physicians to use for both the SPiN Planning™ and SPiN Drive® software applications to assist in the early diagnosis and treatment of lung cancer. New capabilities have also been added for integration of Cone Beam CT, PET scans, and the ability to display blood vessels during both planning and navigation. In addition, Veran has made a great advancement on physician and hospital support with the enhancement of vSupport™ Connect, an on-demand secure screen sharing for live physician directed clinical support.
Veran Medical will also debut a new Always-On Tip Tracked® Triple Needle Brush. This electromagnetic tip tracked tool will help physicians take more samples to assist in the early diagnosis of lung cancer. Since this new instrument will be tip tracked, physicians will not need to use fluoroscopy during sampling.
"The expanding adoption of lung cancer screening has given us a real opportunity to catch cancer earlier and save lives, but only if we can help physicians reach the smallest nodules," said Veran Medical CEO Jason Pesterfield. "Our new software applications and Always-On Tip Tracked® Triple Needle Brush provide additional flexibility to help physicians reach and guide treatment for early stage cancer when patients have the best prognosis."
Veran's next generation SPiN Thoracic Navigation System™ offers an industry leading precision thoracic guidance platform that allows lung specialists to seamlessly transition between a navigated endobronchial approach and a navigated transthoracic approach utilizing SPiN Perc™, to help physicians diagnose lung cancer earlier. A published clinical study utilizing a multi-modality approach, including Veran's SPiN System™ and SPiN Perc™, have demonstrated a 92% diagnostic yield.
Lung Cancer remains the number one cancer killer worldwide. 94 million current or former smokers remain at elevated risk in the U.S. alone. More than 8 million people in the U.S. currently meet the criteria for lung cancer screening. When suspicious lesions are discovered, patients need answers. But mounting clinical data suggests that a large percentage of the hundreds of thousands of bronchoscopies performed every year on suspected lung cancer patients are non-diagnostic—delaying potential lifesaving therapy.
About Veran Medical Technologies
Veran is a privately held medical device company headquartered in St. Louis, MO. The company's mission is to empower physicians to diagnose cancer earlier and to enable precision therapy to save lives. In the United States, lung cancer kills more people each year than breast, prostate, pancreatic and colon cancers combined.
Veran has developed and commercialized an FDA cleared, next generation electromagnetic thoracic navigation platform called the SPiN Thoracic Navigation System™. Veran's breakthrough technology has been adopted by leading cancer centers throughout the United States. Veran provides physicians with a full line of bronchoscopic brushes, needles, forceps and steerable catheters with tiny electromagnetic sensors embedded in the tips for precise navigation. The combination of these proprietary Always-On Tip Tracked® instruments and Veran's exclusive patient respiratory gating technology enables physicians to accurately access lung nodules by accounting for nodule movement during patient breathing, a common challenge for lung specialists.
Another challenge lung specialists face is that approximately 40% of lung nodules lie outside of an airway, making them very difficult to reach endobronchially, and traditionally requiring an additional procedure. Veran's SPiN Thoracic Navigation System™ is the first and only FDA cleared technology that enables Pulmonologists or Thoracic Surgeons the ability to safely and accurately access lung nodules outside of an airway using SPiN Perc™, a navigated transthoracic needle. With SPiN Perc™, Veran combines endobronchial navigation with percutaneous navigation, allowing physicians to access all lung nodules in a single procedure, regardless of nodule size or location. This eliminates the cost and risk of unnecessary procedures and empowers physicians to provide a same day diagnosis for their patients. The early diagnosis and treatment of lung cancer has been proven to save lives.
SOURCE Veran Medical
